Literature DB >> 9509544

Diagnosis and management of early non-immune hydrops fetalis.

E Jauniaux1.   

Abstract

Fetal hydrops is a common symptom of fetal disease at any stage of gestation. The aetiological mechanisms leading to non-immune fetal hydrops are complex and their impact variable at different stages of gestation. In early pregnancy, primary or secondary intra-uterine cardiac failures due to major cardiovascular defects are more often linked to a chromosomal abnormality than during the second half of gestation. In these cases, an increase of the nuchal translucency thickness is probably the first stage of fetal hydrops. Depending on the severity of the underlying defect, the next stage is generalized skin oedema with eventual placental oedema, ascites and pleural effusion. The natural history of fetal hydrops remains poorly understood and thus the prognostic factors determining fetal outcome are still unknown. Examination of the fetal nuchal anatomy between 10 and 15 weeks of gestation and the follow-up of these pregnancies offer an opportunity for an early screening in most aneuploidies and cardiovascular defects, and a better understanding of the aetiopathology of fetal hydrops.

Entities:  

Mesh:

Year:  1997        PMID: 9509544     DOI: 10.1002/(sici)1097-0223(199712)17:13<1261::aid-pd292>3.0.co;2-c

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  2 in total

1.  Percutaneous in utero thoracoamniotic shunt creation for fetal thoracic abnormalities leading to nonimmune hydrops.

Authors:  Sarah B White; Sean M Tutton; William S Rilling; Randall S Kuhlmann; Erika L Peterson; Thomas R Wigton; Mary B Ames
Journal:  J Vasc Interv Radiol       Date:  2014-04-01       Impact factor: 3.464

2.  Is Fetal Hydrops in Turner Syndrome a Risk Factor for the Development of Maternal Mirror Syndrome?

Authors:  Ivonne Alexandra Bedei; Alexander Graf; Karl-Philipp Gloning; Matthias Meyer-Wittkopf; Daria Willner; Martin Krapp; Sabine Hentze; Alexander Scharf; Jan Degenhardt; Kai-Sven Heling; Peter Kozlowski; Kathrin Trautmann; Kai Jahns; Anne Geipel; Ismail Tekesin; Michael Elsässer; Lucas Wilhelm; Ingo Gottschalk; Jan-Erik Baumüller; Cahit Birdir; Felix Zöllner; Aline Wolter; Johanna Schenk; Tascha Gehrke; Corinna Keil; Jimmy Espinosa; Roland Axt-Fliedner
Journal:  J Clin Med       Date:  2022-08-05       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.